Kevin Oeffinger
Overview:
Kevin Oeffinger, MD, is a family physician, Professor in the Department of Medicine, and a member of the Duke Cancer Institute (DCI). He is founding Director of the DCI Center for Onco-Primary Care, and Director of the DCI Supportive Care and Survivorship Center. He has a long-standing track record of NIH-supported research in cancer screening and survivorship and has served in a leadership capacity in various cancer-focused and primary care-focused national committees and organizations, including the American Society of Clinical Oncology, the American Cancer Society, and the American Academy of Family Physicians. He is currently an Associate Editor for the Journal of the National Cancer Institute.
The three-fold mission of the DCI Center for Onco-Primary Care are are to: (1) deliver evidence-based, patient-centered, personalized health care across the cancer continuum by enhancing the interface between cancer specialists and primary care clinicians; (2) conduct innovative research with cutting-edge technology that can be translated to the community setting; and (3) train and educate the next generation of clinicians and researchers to extend this mission.
Dr. Oeffinger's clinical expertise is managing survivors of pediatric and young adult cancer.
Positions:
Professor of Medicine
Professor in the Department of Family Medicine and Community Health
Professor in Population Health Sciences
Member of the Duke Cancer Institute
Education:
M.D. 1984
Family Medicine Internship and Residency
Family Medicine Academic Fellowship
Advanced Research Training, Epidemiology And Genetics, Radiation Epidemiology
Grants:
EMPOWER Study: Promoting BC Screening in Women Who Survived Childhood Cancer
Improving Treatment of Cardiovascular Risk Factors in Childhood Cancer Survivors
Childhood Cancer Survivor Study (CCSS)
Generic Testing to Guide Pediatric Cancer Care and Follow Up: Using Anthracycline-associated Cardiac Toxicity as a Model for the Future
Exercise and QUality diet After Leukemia
Publications:
Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy
Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort.
Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer.
Clinician Perspectives on Managing Chronic Pain After Curative-Intent Cancer Treatment.
Genome-Wide Association Study Identifies ROBO2 as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors.
